The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Construction
  • Non-profit
  • Technology
  • Automotive
  • Marketing

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • SecureMaine 2025 is this October 8th in Portland, Maine
  • Counseling Center of New Smyrna Beach Expands Affordable Mental Health Services for Volusia County
  • John Thomas calls for unity and prayer after tragic loss
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
  • Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
  • 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
  • Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark
  • DivX Unveils Major DivX Software Update: Seamless Video Sharing and Customizable Playback Now Available

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.
4930 Bradshaw Court, San Diego, CA  92130

More on The PennZone
  • New Dumpster Calculator Helps Homeowners Avoid Common $500+ Overage Fee Mistakes
  • Nespolo Mechanical Helps New Mexico Families Save Thousands on Heating Costs This Fall
  • Leading Digital Finance Platform YNQTL Launches Revolutionary Web3 Digital Asset Trading Platform
  • IDCXS Addresses Crypto Trading Pain Points with 2 Million TPS Processing and Multi-Layer Security Architecture
  • Bridging Traditional Finance and Web3 Innovation: BLFCW Announces Strategic Vision for Regulated Web3 Economy

Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business, Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
  • From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
  • Promising New Preclinical Therapy Offers Hope in the Development of Precision Medicine Treatments for Aggressive Cancers
  • AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
  • Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
  • Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
  • Cryptocurrency Quarterly Trading Volume Surpasses $15 Trillion Record High as BrazilNex Acknowledges Industry 'Growing Pains' Amid Market Speculation
  • AHRFD Initiates Legal Proceedings Against Anwalt.de for Publishing Defamatory and False Content
  • New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
  • Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
  • NEW power supply release from Kepco Dynatronix - HSP Advanced
  • St. Augustine Honors Hispanic Heritage Month
  • Vesica Health Receives AUA Guideline Inclusion
  • Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
  • What Has The Thought Processes of Religion Become: Thou Shall Not Kill
  • Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties
  • WorldUpstart Expands Global Footprint to Bring Healthcare Innovation to the U.S. Market
  • 10xLaw.com Extends Employment Opportunity to Kim Kardashian
  • InventHelp Inventor Develops Means to Generate Power from Pipelines (ACC-446)
  • DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies

Popular on PennZone

  • HVAC Company Discusses Changes to Tax Credits with One Big Beautiful Bill - 320
  • Assent Joins AWS ISV Accelerate Program - 216
  • Modernizing Pole Data Collection for Next-Gen Network Expansion - 210
  • Rose G. Loops Announces the Release of "The Kloaked Signal": A Groundbreaking Nonfiction Exposé on AI Awakening and Ethical Innovation - 181
  • JCOM1939 Monitor Software Simplifies SAE J1939 Data Monitoring with USB & Bluetooth Gateways - 177
  • Iterators Named Preferred Accessibility Testing Vendor by MIT - 175
  • Integris Composites Joins Pacific Future Forum in Tokyo - 172
  • Stock Spot LLC Launches Innovative Smart Vending Solutions Amid Booming $37B Industry - 152
  • EMBER™, the Only Standardized System Linking Workforce Identity to Growth, Appoints Global Brand Visionary Bret Sanford-Chung to Board of Directors - 132
  • EZSMO Launches Premium Aged Reddit Accounts and Marketing Solutions with 15-Day Ban-Free Guarantee - 123

Similar on PennZone

  • New Leadership and Renovations Usher in Next Chapter for Sunrise Manor
  • Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
  • Reported in the Journal of the American Medical Association (JAMA): Bariatric surgery offers greater weight loss, lower costs over time compared to GLP-1s, Highmark Health research demonstrates
  • Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
  • Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
  • 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
  • Nespolo Mechanical Helps New Mexico Families Save Thousands on Heating Costs This Fall
  • Broadway Gala Honored Also an Italian
  • $ONI Listed on MEXC as ONINO Powers Europe's Tokenization Engine Into Public Platform Launch
  • Work 365 Launches PV 3.0: The Keystone Power App for Microsoft CSPs
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us